2025
Extracellular Vesicle (EV) Targeted Cells Release Secondary Effector EVs: Indication of How To Account for Histocompatibility and Disease Specificity of EV Treatments
Askenase P. Extracellular Vesicle (EV) Targeted Cells Release Secondary Effector EVs: Indication of How To Account for Histocompatibility and Disease Specificity of EV Treatments. Journal Of Extracellular Vesicles 2025, 14: e70076. PMID: 40415199, PMCID: PMC12104073, DOI: 10.1002/jev2.70076.Peer-Reviewed Original ResearchConceptsMesenchymal stromal cellsSpinal cord injuryT cellsExtracellular vesiclesEffector T cellsSuppressor T cellsDisease specificityTreating spinal cord injuryImmune toleranceHistocompatibility barriersRecipient macrophagesEV treatmentStromal cellsTarget cellsCord injuryMSC-derivedPathological conditionsDiverse injuriesCellsInjuryDiseasePer treatmentTreatmentHealingHealing effect
2011
Pretransplant CSF-1 therapy expands recipient macrophages and ameliorates GVHD after allogeneic hematopoietic cell transplantation
Hashimoto D, Chow A, Greter M, Saenger Y, Kwan W, Leboeuf M, Ginhoux F, Ochando J, Kunisaki Y, van Rooijen N, Liu C, Teshima T, Heeger P, Stanley E, Frenette P, Merad M. Pretransplant CSF-1 therapy expands recipient macrophages and ameliorates GVHD after allogeneic hematopoietic cell transplantation. Journal Of Experimental Medicine 2011, 208: 1069-1082. PMID: 21536742, PMCID: PMC3092347, DOI: 10.1084/jem.20101709.Peer-Reviewed Original ResearchConceptsDonor allogeneic T cellsDonor T cell expansionAllogeneic hematopoietic cell transplantationAllogeneic T cellsHematopoietic cell transplantationAllo-HCTT cell expansionT cellsAcute GVHDCell transplantationHost macrophagesHost antigen-presenting cellsMacrophage poolPotential prophylactic therapyAlloreactive T cellsAntigen-presenting cellsAcute graftGVHD morbidityGVHD mortalityHost DCsHost diseaseProphylactic therapyRecipient miceGVHDRecipient macrophages
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply